Quarterly ResultAug 12, 2026, 09:37 AM
Monopar Q2 Net Loss $5.3M; Initiates ALXN1840 NDA Submission
AI Summary
Monopar Therapeutics reported its second quarter 2026 financial results, showing a net loss of $5.3 million, an increase from $2.5 million in the prior year. The company also provided significant business updates, including the initiation of a rolling New Drug Application (NDA) submission for ALXN1840 for Wilson Disease and the granting of Rare Pediatric Disease (RPD) designation for the same drug. Monopar's cash, cash equivalents, and investments stood at $134.3 million, projected to fund operations through at least December 2027.
Key Highlights
- Initiated rolling submission of New Drug Application (NDA) for ALXN1840 to the FDA on July 22, 2026.
- ALXN1840 granted Rare Pediatric Disease (RPD) designation by the FDA on June 30, 2026.
- Cash, cash equivalents, and investments were $134.3 million as of June 30, 2026.
- Net loss for Q2 2026 was $5.3 million ($0.62 per share), compared to $2.5 million ($0.35 per share) in Q2 2025.
- R&D expenses increased by $3.0 million to $4.8 million in Q2 2026 from $1.7 million in Q2 2025.
- G&A expenses increased by $0.4 million to $1.9 million in Q2 2026 from $1.5 million in Q2 2025.
- Interest income rose to $1.3 million in Q2 2026 from $0.8 million in Q2 2025.
- Current funds are expected to support operations through at least December 31, 2027.
Price Impact
More from MNPR